Ozanimod Did Not Appear to Lead to More Adverse Pregnancy Outcomes

(MedPage Today) -- ORLANDO -- Women with inflammatory bowel disease or relapsing multiple sclerosis who became pregnant while taking the sphingosine-1-phosphate (S1P) receptor modulator ozanimod (Zeposia) did not appear to have a higher risk...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news